Interferon-β1a administration results in a transient increase of serum amyloid A protein and C-reactive protein:: comparison with other markers of inflammation

被引:17
作者
Boylan, MT
Crockard, AD
Duddy, ME
Armstrong, MA
McMillan, SA
Hawkins, SA
机构
[1] Queens Univ Belfast, Royal Grp Hosp Trust, Dept Microbiol & Immunobiol, Belfast BT12 6BA, Antrim, North Ireland
[2] Royal Grp Hosp Trust, Reg Immunol Lab, Belfast BT12 6BA, Antrim, North Ireland
[3] Queens Univ Belfast, Royal Grp Hosp Trust, Dept Med, Belfast BT12 6BA, Antrim, North Ireland
关键词
interferon-beta; multiple sclerosis; serum amyloid A protein; C-reactive protein; mononuclear leukocytes;
D O I
10.1016/S0165-2478(00)00310-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Putative markers of inflammation such as serum beta2-microglobulin and neopterin have been shown to be transiently upregulated following interferon-beta (IFN-beta) administration to multiple sclerosis (MS) patients. However, to date the role of the important inflammatory mediators serum amyloid A protein (SAA) and C-reactive protein (CRP) have not been described. Here we show that SAA but not CRP is elevated in relapsing-remitting MS patients compared to normal healthy individuals; and furthermore that both are transiently upregulated following intramuscular injection with IFN-beta 1a (Avonex(TM)). This pattern of expression was found to parallel that of beta2-microglobulin and neopterin following injection and was mirrored by a selective activation of peripheral monocytes with respect to upregulation of receptors known to be involved in the inflammatory response (HLA-DR, CD16 and CD86). Injection of saline solution intramuscularly to six healthy control individuals did not produce a similar upregulation of any of the inflammatory markers investigated. Following IFN-beta 1a injection, all inflammatory responses were attenuated at week 12 of therapy in comparison to those following the initial injection in a group of follow-up patients. In addition, IFN-beta 1a injected on a weekly basis did not produce a sustained modulation of any of the markers investigated in patients treated for 32 weeks. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 37 条
[1]   Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers [J].
Alam, J ;
Goelz, S ;
Rioux, P ;
Scaramucci, J ;
Jones, W ;
McAllister, A ;
Campion, M ;
Rogge, M .
PHARMACEUTICAL RESEARCH, 1997, 14 (04) :546-549
[2]   Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration [J].
Alam, J ;
McAllister, A ;
Scaramucci, J ;
Jones, W ;
Rogge, M .
CLINICAL DRUG INVESTIGATION, 1997, 14 (01) :35-43
[3]   SERUM AMYLOID-A IS A CHEMOATTRACTANT - INDUCTION OF MIGRATION, ADHESION, AND TISSUE INFILTRATION OF MONOCYTES AND POLYMORPHONUCLEAR LEUKOCYTES [J].
BADOLATO, R ;
WANG, JM ;
MURPHY, WJ ;
LLOYD, AR ;
MICHIEL, DF ;
BAUSSERMAN, LL ;
KELVIN, DJ ;
OPPENHEIM, JJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :203-209
[4]   INDUCTION OF INFLAMMATORY CYTOKINE RELEASE FROM CULTURED HUMAN MONOCYTES BY C-REACTIVE PROTEIN [J].
BALLOU, SP ;
LOZANSKI, G .
CYTOKINE, 1992, 4 (05) :361-368
[5]   PHARMACOKINETICS OF RECOMBINANT HUMAN INTERFERON-BETA(SER) IN HEALTHY-VOLUNTEERS AND ITS EFFECT ON SERUM NEOPTERIN [J].
CHIANG, J ;
GLOFF, CA ;
YOSHIZAWA, CN ;
WILLIAMS, GJ .
PHARMACEUTICAL RESEARCH, 1993, 10 (04) :567-572
[6]  
CROWELL RE, 1991, J IMMUNOL, V147, P3445
[7]   Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b [J].
Dayal, AS ;
Jensen, MA ;
Lledo, A ;
Arnason, BGW .
NEUROLOGY, 1995, 45 (12) :2173-2177
[8]   Changes in plasma cytokines induced by interferon-β1a treatment in patients with multiple sclerosis [J].
Duddy, ME ;
Armstrong, MA ;
Crockard, AD ;
Hawkins, SA .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 101 (01) :98-109
[9]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[10]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504